35,788 Shares in Puma Biotechnology Inc (PBYI) Acquired by Sanctuary Wealth Advisors LLC
Sanctuary Wealth Advisors LLC acquired a new stake in shares of Puma Biotechnology Inc (NYSE:PBYI) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 35,788 shares of the biopharmaceutical company’s stock, valued at approximately $4,286,000. Puma Biotechnology comprises 3.3% of Sanctuary Wealth Advisors LLC’s portfolio, making the stock its 3rd largest holding. Sanctuary Wealth Advisors LLC owned approximately 0.10% of Puma Biotechnology as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Puma Biotechnology by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 2,474,644 shares of the biopharmaceutical company’s stock worth $216,284,000 after purchasing an additional 45,735 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Puma Biotechnology in the 2nd quarter worth $162,302,000. BlackRock Inc. raised its position in shares of Puma Biotechnology by 5.0% in the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock worth $159,973,000 after buying an additional 86,924 shares during the period. Franklin Resources Inc. purchased a new position in shares of Puma Biotechnology in the 2nd quarter worth $50,134,000. Finally, Emerald Advisers Inc. PA raised its position in shares of Puma Biotechnology by 16.5% in the 3rd quarter. Emerald Advisers Inc. PA now owns 370,035 shares of the biopharmaceutical company’s stock worth $44,312,000 after buying an additional 52,355 shares during the period. 80.98% of the stock is owned by hedge funds and other institutional investors.
In other news, SVP Richard Paul Bryce sold 15,000 shares of Puma Biotechnology stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the sale, the senior vice president now owns 42,239 shares of the company’s stock, valued at $5,068,680. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 22.70% of the company’s stock.
Several research analysts recently weighed in on PBYI shares. Credit Suisse Group reaffirmed an “outperform” rating and issued a $118.00 target price (up from $90.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Stifel Nicolaus reissued a “buy” rating and issued a $118.00 price objective (up from $105.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Citigroup Inc. reissued a “buy” rating and issued a $114.00 price objective on shares of Puma Biotechnology in a research report on Tuesday, July 18th. J P Morgan Chase & Co restated a “buy” rating on shares of Puma Biotechnology in a research note on Tuesday, July 18th. Finally, Royal Bank Of Canada set a $88.00 target price on Puma Biotechnology and gave the company a “hold” rating in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Puma Biotechnology currently has a consensus rating of “Buy” and a consensus price target of $130.67.
Shares of Puma Biotechnology Inc (NYSE PBYI) traded down $24.20 during midday trading on Monday, reaching $103.00. 5,677,100 shares of the company’s stock were exchanged, compared to its average volume of 1,118,516. Puma Biotechnology Inc has a 1 year low of $28.35 and a 1 year high of $136.90.
Puma Biotechnology (NYSE:PBYI) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same period last year, the firm posted ($1.11) EPS.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.